VEGFA and age-related macular degeneration: In this study, we enrolled only patients with serous PED secondary to PCV refractory to previous anti-VEGF treatment, and treated patients only with brolucizumab, a new anti-VEGF agent, which showed favorable anatomic and functional outcomes in n-AMD [18].